Additionally, the 36-month beta value for ALVR is 0.67. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average price predicted by analysts for ALVR is $19.75, which is $17.6 above the current price. The public float for ALVR is 57.87M and currently, short sellers hold a 14.36% ratio of that float. The average trading volume of ALVR on September 19, 2023 was 964.26K shares.
ALVR) stock’s latest price update
AlloVir Inc. (NASDAQ: ALVR)’s stock price has gone decline by -14.34 in comparison to its previous close of 2.51, however, the company has experienced a -24.30% decrease in its stock price over the last five trading days. Business Wire reported 2023-08-28 that WALTHAM, Mass.–(BUSINESS WIRE)–AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference Fireside Chat: Monday, September 11, 2023 at 4:55 pm ET H.C. Wainwright 25th Annual Global Investment Conference Presentation: Tuesday, September 12, 2023 at 12:00 pm ET A live webcast.
ALVR’s Market Performance
AlloVir Inc. (ALVR) has seen a -24.30% fall in stock performance for the week, with a -12.96% decline in the past month and a -59.43% plunge in the past quarter. The volatility ratio for the week is 12.86%, and the volatility levels for the past 30 days are at 10.39% for ALVR. The simple moving average for the last 20 days is -28.29% for ALVR’s stock, with a simple moving average of -52.74% for the last 200 days.
Analysts’ Opinion of ALVR
Many brokerage firms have already submitted their reports for ALVR stocks, with BofA Securities repeating the rating for ALVR by listing it as a “Buy.” The predicted price for ALVR in the upcoming period, according to BofA Securities is $17 based on the research report published on August 18, 2023 of the current year 2023.
ALVR Trading at -30.52% from the 50-Day Moving Average
After a stumble in the market that brought ALVR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.11% of loss for the given period.
Volatility was left at 10.39%, however, over the last 30 days, the volatility rate increased by 12.86%, as shares sank -24.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.02% lower at present.
During the last 5 trading sessions, ALVR fell by -24.30%, which changed the moving average for the period of 200-days by -70.01% in comparison to the 20-day moving average, which settled at $2.96. In addition, AlloVir Inc. saw -58.09% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ALVR starting from Brainard Diana, who sale 4,055 shares at the price of $2.79 back on Aug 18. After this action, Brainard Diana now owns 891,883 shares of AlloVir Inc., valued at $11,313 using the latest closing price.
Brainard Diana, the Chief Executive Officer of AlloVir Inc., sale 11,361 shares at $2.50 during a trade that took place back on Aug 17, which means that Brainard Diana is holding 895,938 shares at $28,351 based on the most recent closing price.
Stock Fundamentals for ALVR
The total capital return value is set at -66.46, while invested capital returns managed to touch -67.28. Equity return is now at value -74.00, with -60.70 for asset returns.
Based on AlloVir Inc. (ALVR), the company’s capital structure generated 15.76 points at debt to equity in total, while total debt to capital is 13.62. Total debt to assets is 12.77, with long-term debt to equity ratio resting at 12.57. Finally, the long-term debt to capital ratio is 10.86.
The liquidity ratio also appears to be rather interesting for investors as it stands at 9.99.
In conclusion, AlloVir Inc. (ALVR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.